Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). Type II diabetes is a civilisation disease that has now reached epidemic status. The lack of therapy that can permanently modify the condition without inducing long-term side effects poses a challenge to research centres and pharmaceutical companies. Celon Pharma is currently in the preclinical phase of development of an innovative drug that activates the previously unused therapeutically unused GPR40 receptor, which in vivo reveals a strong antidiabetic effect with minimal risk of side effects. It is therefore a serious competition for medicines available on the market and introduces a new alternative to treatment for patients. The company plans to develop the drug into the final form, i.e. oral dry form, and bring it to Phase II clinical trials confirming its effectiveness and safety in patients. The project will be carried out in four stages, each bringing a milestone of nature: chemical (synthesis of a compound in the GMP regime), biological (determination of safe dose), medical (evidence of real efficiency) and administrative (patent). The structure of the drug itself is currently patented, while the results of detailed studies will be revealed and published in specialised scientific journals. During its work in the field of molecular medicine, the company will outsource some of its tasks to external entities and at key moments of the project will conduct substantive consultations with selected, national clinical consultants.